Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now     
Bio B2B 〉Phytohealth Corp.

Phytohealth Corp.

Chat Now My Favorites
    PhytoHealth Corporation, a member of Maywufa Biopharma Group of companies, was incorporated in 1998 as a new drug development company with focus on research & development, clinical trial, manufacturing, marketing & sales of novel botanical drugs and chemically synthesized drugs.PhytoHealth successfully held its IPO in 2002, being the first new drug development company to be listed on the Taiwan stock market (No. 4108).
    In 2010, PhytoHealth acquired Taiwan's first new drug designation for PHN012® and invested hundreds of millions to build Taiwan's first GMP sterile botanical drug manufacturing facility that is in compliance with PIC/S (Guide to Good Manufacturing Practice for Medical Products) and FDA regulations. This step symbolizes a milestone in the new injectable botanical drug manufacturing technology in Taiwan's domestic biotechnology industry. PHN012® hit the market to supply major hospitals in late April 2012. Leveraging on PhytoHealth's R&D strength and Maywufa's marketing experience, PHN012® is marketed by the pharmaceutical marketing team under the Maywufa Biopharma Group and is supplied to major hospitals across Taiwan to help alleviate severe and incurable cancer-related fatigue syndrome. The use of PHN012® has been expanded to treat stroke patients, and continued implementation of clinical trials by a stroke specialist Medical Center.
PhytoHealth's business strategy is to “authorize international pharmaceutical companies to jointly open up the markets in Europe and the US while retaining marketing control in Asian countries (excluding Japan)".
    Not only has PhytoHealth created Taiwan's first new botanical drug, PHN012®, that drug was approved by the FDA for four additional clinical trials. With its high industrial standards and numerous award-winning studies, PhytoHealth is certainly the industry leader in the huge botanical drug market of China, which involves limitless business opportunities and potential.
   “Asian leader, Global niche" PhytoHealth has become the leader in botanical drug development in Asia. PhytoHealth is definitely the first choice of many major international pharmaceutical companies when they seek Asian business partners.
  • C. C. Lee<br/>Chairman of the Board

    C. C. Lee
    Chairman of the Board

    -Founder ; Chairman of the Maywufa Biopharma Group ; Director,The Central Bank of the Republic of China (Taiwan);National Policy Advisor to the President;EMBA, National Cheng Chi University
  • K. C. Chen<br/>Vice Chairman

    K. C. Chen
    Vice Chairman

    -Vice chairman of AmCad; B.S. in Pharmacy, National Taiwan University;1980 Executive Program Graduate School of business, Indiana State University, U.S.A
  • Dr. C. H. Cheng<br/>President

    Dr. C. H. Cheng
    President

    -Vice/Acting President, Development Center for Biotechnology, New Taipei City, Taiwan; Ph.D. Chemical Engineering, University of Michigan, Ann Arbor, MI, USA
  • Yili Lee<br/>Executive Director

    Yili Lee
    Executive Director

    -Executive Director ,Maywufa Biopharma group.; Director, International Global Corporate, Standard Chartered Bank; BBA in Finance, National Taiwan University
  • Dr. Gary Lin <br/>Vice President,B.D.

    Dr. Gary Lin
    Vice President,B.D.

    -Manager & Researcher: Taiwan Liposome Company, Ltd. (TLC) (Taiwan); National Yang Ming University, Doctor of Philosophy (Ph.D.), Pharmacology (Taiwan)
    PhytoHealth Corporation, a member of Maywufa Biopharma Group of companies, was incorporated in 1998 as a new drug development company with focus on research & development, clinical trial, manufacturing, marketing & sales of novel botanical drugs and chemically synthesized drugs.PhytoHealth successfully held its IPO in 2002, being the first new drug development company to be listed on the Taiwan stock market (No. 4108).
    In 2010, PhytoHealth acquired Taiwan's first new drug designation for PHN012® and invested hundreds of millions to build Taiwan's first GMP sterile botanical drug manufacturing facility that is in compliance with PIC/S (Guide to Good Manufacturing Practice for Medical Products) and FDA regulations. This step symbolizes a milestone in the new injectable botanical drug manufacturing technology in Taiwan's domestic biotechnology industry. PHN012® hit the market to supply major hospitals in late April 2012. Leveraging on PhytoHealth's R&D strength and Maywufa's marketing experience, PHN012® is marketed by the pharmaceutical marketing team under the Maywufa Biopharma Group and is supplied to major hospitals across Taiwan to help alleviate severe and incurable cancer-related fatigue syndrome. The use of PHN012® has been expanded to treat stroke patients, and continued implementation of clinical trials by a stroke specialist Medical Center.
PhytoHealth's business strategy is to “authorize international pharmaceutical companies to jointly open up the markets in Europe and the US while retaining marketing control in Asian countries (excluding Japan)".
    Not only has PhytoHealth created Taiwan's first new botanical drug, PHN012®, that drug was approved by the FDA for four additional clinical trials. With its high industrial standards and numerous award-winning studies, PhytoHealth is certainly the industry leader in the huge botanical drug market of China, which involves limitless business opportunities and potential.
   “Asian leader, Global niche" PhytoHealth has become the leader in botanical drug development in Asia. PhytoHealth is definitely the first choice of many major international pharmaceutical companies when they seek Asian business partners.
  Video
Pipeline & Platform